Sept. 6, 2012
Life Technologies Corporation
(NASDAQ: LIFE) today announced another major advancement in the performance trajectory of its Ion AmpliSeq Technology. The new Torrent Suite Software v3.0 now consistently delivers 99.99+% consensus accuracy for both short and long homopolymer regions, and increases the frequency of correctly called insertions, deletions and homopolymer sequences by two-fold.
Read length on the Ion PGM™ also continues its unprecedented scalability with today's launch of the 400 base sequencing kits, which will provide a broader range of applications, such as bacterial identification, metagenomic analysis, Human Leukocyte Antigen sequencing, and better
"Ion's new long read kits combined with accuracy increases from Torrent Suite v3.0 have enabled us to significantly improve the performance of our bacterial and metagenomic sequencing as well as microbial genome assemblies," said Professor
of the University of Muenster,
– a researcher at the epicenter of last year's pathogenic
outbreak. "The rapid generation of long accurate reads by the Ion PGM Sequencer will truly enable the new science of prospective genomic epidemiology."
AmpliSeq™ Technology Transforms Research
Six months after its introduction to the market, Ion AmpliSeq Technology has significantly
transformed the way hypothesis-driven research is conducted
. More than 700 customers have completed over 2,500 gene panel designs and high throughput laboratories have achieved annual run rates of over 1,000 runs per Ion PGM System.
A new Ion AmpliSeq Sample ID Panel reveals sample misidentification to increase confidence during data analysis and reporting. Ion Reporter Software now incorporates oncology and inherited disease trio research workflows. These advances improve the sensitivity and utility of all existing Ion AmpliSeq Panels, as well the soon to be launched Ion AmpliSeq Cancer Panel v2. This new, ready-to-use panel offers additional oncogene content and approaches 100% coverage uniformity, further widening the performance gap relative to competing target enrichment products.